Results about: patients
In EMBO Molecular Medicine, IRB Barcelona scientists report a technique based on a combination of CRISPR/Cas9 genome editing and patient-derived tumour organoids that allows the study of cell heterogeneity in human tumours.
The novel approach was used to examine the behaviour of colorectal cancer stem cells by tracing specific marker genes.
Researchers at IDIBAPS and IRB Barcelona have described in Cancer Research, that the longer the time from the onset of the tumour to the development of metastasis is, the more aggressive this cancer becomes.
Research centres of excellence in Barcelona offer PhD fellowships to medical doctors.
Called PhD4MD, the programme allows medical doctors to carry out a three-year doctoral thesis on cancer, rare disease or neurodegenerative conditions.
It was the first time that Group Leader and ICREA researcher Maria Macias organised a Barcelona BioMed Conference, in collaboration with the BBVA Foundation, held on 28-30 November 2016. When asked about the experience, she highlights that having been able to draw together experts from very diverse research fields and backgrounds was “extremely fulfilling” for her. The conference programme covered areas spanning genomics to systems biology, cellular structural biology, big data, and patients-focussed approaches.
A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.
Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.
In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.
Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.
IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.